Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

The UK company reveals the results from a partner-led survey to discover the rates of vaccination for adults, why levels are lower than expected, and what can be done to improve this. Ben Hargreaves ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has agreed ...

On Friday, the F.D.A. approved a new antibiotic, zoliflodacin, a day after an article published in The Lancet reported that a ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

And GSK announced Thursday that the FDA had approved its medication gepotidacin, with the brand name Blujepa, as oral tablets ...

For the first time in nearly 40 years, the FDA approved a new antibiotic to treat gonorrhea, an STI that has grown ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments ...

Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...

GSK PLC on Friday said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the approval of depemokimab in two indications. The London-based pharmaceutical ...